These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37473683)

  • 21. Targeted therapies for treatment of recurrent ovarian cancer.
    Grisham RN; Hyman DM; Iyer G
    Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
    Webber K; Friedlander M
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():126-138. PubMed ID: 28027849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Lawrie TA; Winter-Roach BA; Heus P; Kitchener HC
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004706. PubMed ID: 26676202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
    Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
    Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
    Li Y; Yang Y; Shang YM; Zheng H
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceutical management of ovarian cancer : current status.
    Markman M
    Drugs; 2008; 68(6):771-89. PubMed ID: 18416585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Winter-Roach BA; Kitchener HC; Lawrie TA
    Cochrane Database Syst Rev; 2012 Mar; 3(3):CD004706. PubMed ID: 22419298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of recurrent ovarian cancer].
    Kudo R; Sagae S
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1991-7. PubMed ID: 1358032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
    Ledermann JA; Embleton AC; Raja F; Perren TJ; Jayson GC; Rustin GJS; Kaye SB; Hirte H; Eisenhauer E; Vaughan M; Friedlander M; González-Martín A; Stark D; Clark E; Farrelly L; Swart AM; Cook A; Kaplan RS; Parmar MKB;
    Lancet; 2016 Mar; 387(10023):1066-1074. PubMed ID: 27025186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Winter-Roach BA; Kitchener HC; Dickinson HO
    Cochrane Database Syst Rev; 2009 Jul; (3):CD004706. PubMed ID: 19588360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line treatment of ovarian cancer.
    Markman M; Bookman MA
    Oncologist; 2000; 5(1):26-35. PubMed ID: 10706647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    Wuntakal R; Seshadri S; Montes A; Lane G
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
    Rocconi RP; Case AS; Straughn JM; Estes JM; Partridge EE
    Cancer; 2006 Aug; 107(3):536-43. PubMed ID: 16804928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer.
    Zhu M; Wang J; Wuna Y; Wang Y; Li H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 46(6):644-652. PubMed ID: 34275934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?
    Ledermann JA; Wheeler S
    Cancer Invest; 2004; 22 Suppl 2():2-10. PubMed ID: 15573740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.